The present invention relates to immunoglobulin chimeric monomer-dimer heterodimers. The present invention relates to chimeric monomer-dimer heterodimeric proteins, wherein said protein comprises a first and second polypeptide chain, wherein said first chain comprises at least a portion of an immunoglobulin constant region and a bioactive molecule, wherein said second chain comprises at least a portion of an immunoglobulin constant region, does not contain the bioactive molecule of the first chain. The present invention also relates to methods of using and preparing the chimeric monomer-dimer heterodimeric proteins of the present invention.
The provided text is a patent application document (CN 102234334 B) filed by Synthetix Pharmaceuticals. It discloses a specific type of chimeric protein known as a monomer-dimer heterodimer.
The invention involves a protein comprising two polypeptide chains. The first chain contains a biologically active molecule (such as interferon, erythropoietin, or coagulation factors) linked to an Fc region that acts as an FcRn binding partner. The second chain contains an Fc region that also acts as an FcRn binding partner but does not contain the biologically active molecule or variable regions. This structure is designed to extend the half-life of the active molecule in the body. This manual is written in Chinese.
Interferon, erythropoietin, and clotting factors.
Viral infection.
Intravenous, subcutaneous, oral, buccal, sublingual, nasal, parenteral, rectal, vaginal, or pulmonary.
The bioactive molecule and the immunoglobulin variable region.